Natco Pharma Completes Acquisition of Additional 13.25% Stake in Adcock Ingram Holdings Proprietary Limited

Natco Pharma Completes Acquisition of Additional 13.25% Stake in Adcock Ingram Holdings Proprietary Limited​

NATCO Pharma Limited has completed the acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, a leading South African pharmaceutical and healthcare company. This successful transaction increases NATCO’s shareholding in Adcock Ingram from 35.75% to 49%.

The acquisition was finalized through NATCO Pharma South Africa Proprietary Limited, which is NATCO's wholly owned subsidiary in South Africa. The transaction involved the purchase of shares for an aggregate consideration amounting to ZAR 1.81 billion, equivalent to ₹ 1,060 crore at the transaction exchange rate.

Strategic Milestone in African Growth Strategy​

The acquisition represents a significant milestone in NATCO’s long-term strategy focused on Africa. This move follows NATCO's initial investment in Adcock Ingram, which was secured when it acquired 35.75% through participation in Adcock Ingram's delisting process in 2025. That prior transaction involved a firm intention offer in July 2025, shareholder approval in October 2025, and completion of the deal in November 2025.

Following that initial investment, NATCO’s Board approved the purchase of an additional 13.25% stake in July 2026. The current transaction was completed after satisfying customary closing conditions and regulatory requirements.

Company Profiles​

NATCO Pharma Limited
Established in 1981, NATCO is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India, holding a market capitalisation of approximately US$ 1.82 billion. The company specializes in pharmaceutical R&D and focusing on high potential niche molecules. Products are manufactured across nine state-of-the-art facilities that are certified and approved by global regulatory authorities such as the US FDA, Brazil's ANVISA, Health Canada, and the World Health Organisation. NATCO Pharma exports its products to more than 50 countries, including the USA, Brazil, and Canada, with a particular focus on oncology, cardiology, and neurology therapeutic categories.

Adcock Ingram Holdings Proprietary Limited
Adcock Ingram is a South African pharmaceutical company founded in 1891, recognized as the second largest entity in the private and public pharmaceutical market of South Africa. The company manufactures, markets, and distributes healthcare products across both private and public sectors. Its product range includes Prescription, Over-the-counter (OTC), Consumer, and Hospital products, manufactured in facilities located in South Africa and India. Key household brands include Panado, Allergex, Epi-max, Citro-Soda, and Myprodol. Adcock Ingram holds a 10% market share of the private market and is identified as the largest supplier of hospital and critical care products in South Africa.

NATCOPHARM Stock Price Movement​

As of 11:55 AM, shares of Natco Pharma Limited are slipping by 1.04% in live trading, currently valued at ₹969.75. The stock has experienced robust intraday activity, with a total traded volume amounting to 138,203 shares.